KAJIAN GLUTATION DAN F2 ISOPROSTAN PADA PASIEN TUBERKULOSIS PARU YANG MENDAPAT TERAPI OBAT ANTI TUBERKULOSIS

Main Article Content

Nurul Hidayah
Ari Yuniastuti

Abstract

Tuberkulosis paru merupakan penyakit menular yang masih mendapat perhatian di dunia.  tujuan dari penelitian ini adalah mengkaji kadar glutation (GSH) dan F2 isoprostan pada pasien TB paru yang belum mendapat dan setelah mendapat terapiOAT. Metode penelitian ini adalah eksperimental Quasi (eksperimental semu), dimana dalam eksperimen ini tidak menggunkan kontrol study kasus dengan rancangan pre dan post. Sampel yang digunakan merupakan pasien TB yang belum mengkonsumsi OAT sebanyak 59pasien umur 15-55 tahun. Darah diambil sebanyak 5ml melalui intra vena. Uji kadar GSH dan F2_Isoprostan kemudian di baca menggunakan Elisa kit pada 450 nm. Hasil penelitian menunjukan bahwa kadar GSH awal 0,052 mM/mL kadar GSH akhir 0,058 mM/mL. Uji t statistik mendapat nilai signifikan 0,05 (P<0,005). Pada kadar F2ISO awal 96,969 Pg/Ml kadar F2ISO akhir 96.578 Pg/MlUjiWilcoxon di dapat nilai sig 0,902 (P>0,05) Simpulanya bahwa kadar GSH pasien sebelum dan setelah mendapat terapi OAT terdapat perbedaan sedangkan pada kadar F2ISO sebelum dan setelah mengkonsumsi OAT tidak terdapat perbedaan, tetapi terdapat hubungan antara GSH dan F2ISO pada pasien tuberkulosis paru

 

Pulmonary tuberculosis is a contagious disease that still gets the attention of the world. the purpose of this study is to examine the levels of glutathione (GSH) and F2 isoprostane in patients with pulmonary TB who have not received OAT and after therapy. This research method is experimental Quasi (quasi-experimental), which in this experiment not using the case control study with pre and post design. The sample used was TB patients who do not consume as much 59pasien OAT aged 15-55 years. Blood taken as 5ml via intravenous. Test the levels of GSH and F2_Isoprostan then be read using Elisa kit at 450 nm. The results showed that the levels of GSH beginning of 0.052 mM / mL final concentration 0.058 mM GSH / mL. T test statistic got significant value of 0.05 (P <0.005). At the beginning F2ISO levels 96.969 Pg / Ml levels F2ISO end 96 578 Pg / Ml in the Wilcoxon test can sig 0.902 (P> 0.05) Simpulanya that GSH levels of patients before and after therapy OAT whereas there are differences in the levels before and after consuming F2ISO OAT there is no difference, but there is a relationship between GSH and F2ISO in patients with pulmonary tuberculosis.

Article Details

Section
Articles

References

Connell ND and Venketaraman V. 2009.Control of Mycobacterium tuberculosis infection by Glutathione Recent Patients on Anti-Infective.Drug Discovery (4): 214-226.
Dayaram YK, Connell ND, Venketaraman V. 2006.Characterization of a glutathione metabolic mutant of Mycobacterium tuberculosis and its resistance to glutathione and Nitrosoglutathione.Jurnal Bacteriology 188: 1364–72.
Milne Gl, Yin H, Hardy KD, Davies SS dan Roberts LJ.2011. Isoprostane generation and function. Chem Rev 111 (100:5973-5996.
Montuschi P, Barnes PJ, Robert LJ 2nd. 2004. Isoprostanes: markers and mediators of oxidative stress. FASEB J 18:1791-800.
Mohod K, Archana D and Smith K. 2011. Status of Oxidants and Antioxidants in Pulmonary Tuberculosis With Varying Bacillary Load. Journal of Experimental Science 2(6):35-37.
Taha DA and Imad AJT. 2010. Antioxidant status, C-Reactive Protein and Status in Patient with Pulmonary tuberculosis. SQU MED.J 10 (3):361-369.
Venketaraman V, Dayaram YK, Talaue MT dan Connell ND. 2005. Glutathione and Nitrosoglutathione in macrophage defense against M. tuberculosis. Infect Immunity 73: 1886–9
World Health Orgnitation. 2010. Global Tuberculosis Programme : Global Tuberculosis Control. WHO Report.
Yuniastuti A. 2013. Status Antioksidan Glutation Pada Pasien Tuberkulosis Paru Di Balai Kesehatan Paru (BKPM) Makasar.Mkasar.Hal : 54-54
Zakiyah, E. R. 2014. Pengaruh Pemberian Vitamin C Terhadap Perubahan Kadar Total Antioksidan Serum Pada Tuberkulosis Paru Anak.. Departemen Ilmu Kesehatan Anak Fakultas Kedokteran Padjajaran. 16(2):110-4.